

Theodoros Karantanos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5646612/publications.pdf>

Version: 2024-02-01

66
papers

2,933
citations

257357

24
h-index

175177

52
g-index

71
all docs

71
docs citations

71
times ranked

6027
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy. <i>Leukemia and Lymphoma</i> , 2022, 63, 1942-1948.	0.6	8
2	The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia. <i>Science Advances</i> , 2022, 8, eabl8952.	4.7	7
3	Abstract 5435: CCRL2 affects the sensitivity of MDS and secondary AML to azacitidine. <i>Cancer Research</i> , 2022, 82, 5435-5435.	0.4	0
4	Sex-Related Differences in Chronic Myeloid Neoplasms: From the Clinical Observation to the Underlying Biology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2595.	1.8	10
5	Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes. <i>British Journal of Haematology</i> , 2021, 193, 1142-1150.	1.2	21
6	Germline ERBB2/HER2 Coding Variants Are Associated with Increased Risk of Myeloproliferative Neoplasms. <i>Cancers</i> , 2021, 13, 3246.	1.7	5
7	Biology and clinical management of hypoplastic MDS: MDS as a bone marrow failure syndrome. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101280.	0.7	11
8	DLST-dependence dictates metabolic heterogeneity in TCA-cycle usage among triple-negative breast cancer. <i>Communications Biology</i> , 2021, 4, 1289.	2.0	30
9	Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1821-1823.	1.3	1
10	Expression of putative leukemia stem cell targets in genetically-defined acute myeloid leukemia subtypes. <i>Leukemia Research</i> , 2020, 99, 106477.	0.4	8
11	Inflammation exerts a nonrandom risk in the acquisition and progression of the MPN: Insights from a Mendelian randomization study. <i>EClinicalMedicine</i> , 2020, 21, 100324.	3.2	2
12	Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden. <i>Blood Advances</i> , 2020, 4, 2567-2576.	2.5	37
13	2019 Brings Biologic Understanding and Hope for Patients With TP53 Mutated Myelodysplastic Syndrome. , 2020, 17, .		0
14	Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN). <i>Blood</i> , 2020, 136, 40-40.	0.6	0
15	The absolute lymphocyte count can predict the overall survival of patients with non-small cell lung cancer on nivolumab: a clinical study. <i>Clinical and Translational Oncology</i> , 2019, 21, 206-212.	1.2	59
16	Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. <i>Clinical Immunology</i> , 2019, 207, 18-23.	1.4	10
17	Acute Myeloid Leukemia Stem Cell Heterogeneity and Its Clinical Relevance. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1139, 153-169.	0.8	23
18	Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease. <i>Frontiers in Immunology</i> , 2019, 10, 295.	2.2	20

#	ARTICLE	IF	CITATIONS
19	Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma. <i>Oncologist</i> , 2019, 24, 146-150.	1.9	5
20	976. Development and Validation of a Risk Score for Predicting Cardiovascular Events in HIV-Infected Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, S35-S36.	0.4	0
21	ATM Germline Variant Increases the Risk of MPN Progression. <i>Blood</i> , 2019, 134, 835-835.	0.6	1
22	Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden. <i>Blood</i> , 2019, 134, 837-837.	0.6	0
23	Salivary Secretory Carcinoma With a Novel ETV6-MET Fusion. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1121-1126.	2.1	96
24	The roles of JAK2 in DNA damage and repair in the myeloproliferative neoplasms: Opportunities for targeted therapy. <i>Blood Reviews</i> , 2018, 32, 426-432.	2.8	12
25	Gender Determines the Myeloproliferative Neoplasms Phenotype Independently of Age, Driver Mutation and JAK2V617F Burden. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S267-S268.	0.2	0
26	Independent Association of Male Sex with Presentation and Clinical Outcomes in Myeloproliferative Neoplasms. <i>Blood</i> , 2018, 132, 1768-1768.	0.6	1
27	Immunotherapy comes of age: Immune aging & checkpoint inhibitors. <i>Journal of Geriatric Oncology</i> , 2017, 8, 229-235.	0.5	108
28	Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. <i>Cell Reports</i> , 2017, 18, 1970-1981.	2.9	83
29	Androgen receptor inhibitor-induced BRCAness and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. <i>Science Signaling</i> , 2017, 10, .	1.6	200
30	Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 103-112.	2.0	4
31	Pyogenic Liver Abscess Due to <i>Fusobacterium nucleatum</i> in a Patient With Liver Hemangiomas. <i>American Journal of the Medical Sciences</i> , 2017, 353, 417-418.	0.4	3
32	Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategies. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2017, Volume 7, 37-52.	1.2	6
33	Regulation of T Cell Differentiation and Function by EZH2. <i>Frontiers in Immunology</i> , 2016, 7, 172.	2.2	70
34	Fecal Colonization With Extended-spectrum Beta-lactamase-Producing <i>Enterobacteriaceae</i> and Risk Factors Among Healthy Individuals: A Systematic Review and Metaanalysis. <i>Clinical Infectious Diseases</i> , 2016, 63, 310-318.	2.9	359
35	Uncontrolled diabetes predicts poor response to novel antiandrogens. <i>Endocrine-Related Cancer</i> , 2016, 23, 691-698.	1.6	14
36	Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 46321-46334.	0.8	22

#	ARTICLE	IF	CITATIONS
37	Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2. <i>Oncotarget</i> , 2016, 7, 85624-85640.	0.8	44
38	JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic function. <i>Translational Cancer Research</i> , 2016, 5, S1208-S1211.	0.4	5
39	Assessing the cardiovascular risk of hormonal therapy in patients with prostate cancer. <i>Annals of Translational Medicine</i> , 2016, 4, 99-99.	0.7	1
40	Synbiotics and gastrointestinal function-related quality of life after elective colorectal cancer resection. <i>Annals of Gastroenterology</i> , 2016, 29, 56-62.	0.4	32
41	Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer. <i>Cancer Biomarkers</i> , 2015, 15, 843-850.	0.8	9
42	GLIPR1- $\hat{1}$ TM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells. <i>Molecular Cancer</i> , 2015, 14, 122.	7.9	24
43	Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level. <i>European Urology</i> , 2015, 67, 470-479.	0.9	225
44	DNA damage response and prostate cancer: defects, regulation and therapeutic implications. <i>Oncogene</i> , 2015, 34, 2815-2822.	2.6	81
45	Clock genes: Their role in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 1986.	1.4	53
46	Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn's disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 3609.	1.4	19
47	Systemic GLIPR1- $\hat{1}$ TM protein as a novel therapeutic approach for prostate cancer. <i>International Journal of Cancer</i> , 2014, 134, 2003-2013.	2.3	10
48	Targeting Poly(ADP-Ribose) Polymerase and the c-Myb-Regulated DNA Damage Response Pathway in Castration-Resistant Prostate Cancer. <i>Science Signaling</i> , 2014, 7, ra47.	1.6	73
49	Do Anastomotic Leaks Impair Postoperative Health-related Quality of Life After Rectal Cancer Surgery? A Case-matched Study. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 158-166.	0.7	44
50	Quality of Life After Laparoscopic Colectomy for Cancer. <i>Journal of the Society of Laparoendoscopic Surgeons</i> , 2014, 18, 225-235.	0.5	11
51	Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance. <i>Asian Journal of Urology</i> , 2014, 1, 30-39.	0.5	1
52	Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. <i>Oncogene</i> , 2013, 32, 5501-5511.	2.6	646
53	Association of the clock genes polymorphisms with colorectal cancer susceptibility. <i>Journal of Surgical Oncology</i> , 2013, 108, 563-567.	0.8	35
54	GEMMs Shine a Light on Resistance to Androgen Deprivation Therapy for Prostate Cancer. <i>Cancer Cell</i> , 2013, 24, 11-13.	7.7	4

#	ARTICLE	IF	CITATIONS
55	Prospective evaluation of health-related quality of life after laparoscopic colectomy for cancer. <i>Techniques in Coloproctology</i> , 2013, 17, 27-38.	0.8	34
56	Post-colectomy assessment of gastrointestinal function: a prospective study on colorectal cancer patients. <i>Techniques in Coloproctology</i> , 2013, 17, 525-536.	0.8	32
57	Immune response after laparoscopic colectomy for cancer: a review. <i>Gastroenterology Report</i> , 2013, 1, 85-94.	0.6	30
58	Expression of Clock Genes in Patients with Colorectal Cancer. <i>International Journal of Biological Markers</i> , 2013, 28, 280-285.	0.7	35
59	Caspase 9 promoter polymorphisms confer increased susceptibility to breast cancer. <i>Cancer Genetics</i> , 2012, 205, 508-512.	0.2	20
60	Probiotics, Prebiotics, Synbiotics: Is There Enough Evidence to Support Their Use in Colorectal Cancer Surgery?. <i>Digestive Surgery</i> , 2012, 29, 426-438.	0.6	29
61	Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development. <i>Breast</i> , 2012, 21, 534-538.	0.9	66
62	5-HT2A Receptor Gene Polymorphisms and Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 514-517.	1.1	16
63	Serotonin Transporter and G Protein Beta 3 Subunit Gene Polymorphisms in Greeks with Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2011, 56, 3276-3280.	1.1	22
64	Inflammatory bowel disease: recent advances on genetics and innate immunity. <i>Annals of Gastroenterology</i> , 2011, 24, 164-172.	0.4	9
65	Vascular endothelial growth factor and endoglin expression in colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 703-708.	1.2	14
66	Current insights in to the pathophysiology of Irritable Bowel Syndrome. <i>Gut Pathogens</i> , 2010, 2, 3.	1.6	67